Wisconsin-based Phillips-Medisize Corporation announced the opening of its new design and development centre in Suzhou, China. Growth of the company’s design and development centres supports its customers’ needs for patient-administered biologics and pharmaceutical drug delivery and diagnostics device design and development services.
The creation of this new design and development centre is in keeping with Phillips-Medisize’s long standing global strategy of providing both regional manufacturing and outsourced design/development support for its global customers. Outsourced design and development services has proven to be important to the company’s customer base as it provides common worldwide quality standards and design controls while allowing for local service and manufacturing support.
As part of the company’s network of design and development centres, the Suzhou facility has multiple capabilities including device design, injection moulding simulation, developmental tooling and assembly equipment, along with on-site programme management.
This design and development group is actively working on multiple projects, including biologics drug delivery devices intended specifically for Asian markets.
Matt Jennings, Chairman and CEO of Phillips-Medisize Corporation said that the new Suzhou design and development centre will support the customers’ need for outsourced design and develop of new market appropriate products for the Asian market.
The company’s network of four design centres located in North America, Europe and now Asia, employ approximately 200 engineering professionals, while the global program management and new product introduction teams of 275 engineering professionals successfully drove the launch of 81 new products in 2014. Traditionally, over 80% of the new drug delivery, diagnostic, and med-tech products the company launches have their roots within the Phillips-Medisize design and development organisation.